Skip to content

Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes

Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Type II Diabetes Mellitus

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03358264
Enrollment
50
Registered
2017-11-30
Start date
2017-01-01
Completion date
2018-12-31
Last updated
2017-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Vascular dysfunction, L-citrulline, arginase

Brief summary

Arginase has recently been implicated in an array of vascular conditions including atherosclerosis , hypertension and vascular complication of diabetes. In this study we will determine of L-citrulline; a natural amino acid that is known to have inhibitory effects on arginase activity, on vascular function in type 2 diabetic patients.

Detailed description

Vascular dysfunction is a major cause of morbidity and mortality in diabetic patients. The pathological process is characterized by impaired endothelial cell production of the vasodilator and antiplatelet adhesion factor nitric oxide (NO) and/or decreased NO bioavailability. NO is a major regulator of vascular tone and integrity. In endothelial cells, NO is produced by activity of endothelial NO synthase (eNOS) on its substrate L-arginine. Reduced availability of L-arginine to eNOS has been implicated in vascular dysfunction in diabetes and a variety of other disease conditions. Arginase, which metabolizes L-arginine to urea and ornithine, competes directly with NOS for L-arginine. Hence increases in arginase activity can decrease tissue and cellular arginine levels, reducing its availability to eNOS and decreasing No production. During diabetes, elevated levels of arginase can compete with NOS for available arginine thus reducing vascular NO. We have recently shown that arginase activity is elevated in diabetes. In this proposal we implement a method of flow mediate dilation (FMD) to assess vascular function in diabetic patients. We will study the relation of our vascular function findings with arginase activity levels. We propose that arginase activity measurements could be novel marker of vascular dysfunction in diabetes. The effect of the natural amino acid supplements (L-citrulline) on levels of arginase activity in diabetic patients and vascular function will also be studied.

Interventions

DIETARY_SUPPLEMENTL-citrulline

Amino acid supplement

Sponsors

University of Jordan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
45 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

Type 2 diabetes Diabetic state: HbA1c\>6

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
arginase activity1 monthLevels of arginase activity enzyme will be measured in plasma in subjects before and after l-citrulline supplementation
Vascular function1 monthforearm vascular function will be assessed by flow mediated dilation of brachial blood vessels before and after L-citrulline supplementation

Countries

Jordan

Contacts

Primary ContactAlia Shatanawi, PhD, DDS
a.shatanawi@ju.edu.jo+96265355000
Backup ContactMunir N Gharaibeh, PhD, MD
mgharaib@ju.edu.jo96265355000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026